Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
复制标题
评估血清 DNA 中表皮生长因子受体突变状态作为吉非替尼 (IRESSA) 反应的预测因子。
DOI：
10.1038/sj.bjc.6603949
复制
发表时间：
2007-09-17
影响因子：
8.8
通讯作者：
Nakao, S.
中科院分区：
文献类型：
--
作者：
Kimura, H.;Suminoe, M.;Kasahara, K.;Sone, T.;Araya, T.;Tamori, S.;Koizumi, F.;Nishio, K.;Miyamoto, K.;Fujimura, M.;Nakao, S.
本研究的目的是评估血清DNA中EGFR突变状态作为预测吉非替尼（易瑞沙）治疗日本非小细胞肺癌（NSCLC）患者获益的一种手段的有效性。我们获得了42例接受吉非替尼治疗的患者的成对肿瘤和血清样本。采用直接测序法和Scorpion Amplification Refractory mutation System （ARMS）技术检测EGFR突变状态。在8例患者的肿瘤样本和7例患者的血清样本中检测到EGFR突变。42对样本中有39对（92.9%）的肿瘤和血清EGFR突变状态一致。肿瘤样本和血清样本中的EGFR突变状态与对吉非替尼的客观反应之间存在强相关性（P<0.001）。EGFR突变患者的中位无进展生存时间明显长于无EGFR突变患者（肿瘤样本中194天对55天，P=0.016；血清样本中174天对58天，P=0.044）。结果表明，利用血清DNA检测EGFR突变是可行的，并且有可能作为吉非替尼应答和生存的预测指标，值得进一步评价。
The aim of this study was to evaluate the usefulness of EGFR mutation status in serum DNA as a means of predicting a benefit from gefitinib (IRESSA) therapy in Japanese patients with non-small cell lung cancer (NSCLC). We obtained pairs of tumour and serum samples from 42 patients treated with gefitinib. EGFR mutation status was determined by a direct sequencing method and by Scorpion Amplification Refractory Mutation System (ARMS) technology. EGFR mutations were detected in the tumour samples of eight patients and in the serum samples of seven patients. EGFR mutation status in the tumours and serum samples was consistent in 39 (92.9%) of the 42 pairs. EGFR mutations were strong correlations between both EGFR mutation status in the tumour samples and serum samples and objective response to gefitinib (P<0.001). Median progression-free survival time was significantly longer in the patients with EGFR mutations than in the patients without EGFR mutations (194 vs 55 days, P=0.016, in tumour samples; 174 vs 58 days, P=0.044, in serum samples). The results suggest that it is feasible to use serum DNA to detect EGFR mutation, and that it's potential as a predictor of response to, and survival on gefitinib is worthy of further evaluation.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
158.5
作者：
Sandler, Alan;Gray, Robert;Johnson, David H.
通讯作者：
Johnson, David H.
影响因子：
82.9
作者：
Nawroz, H;Koch, W;Sidransky, D
通讯作者：
Sidransky, D
影响因子：
254.7
作者：
Parkin, DM;Bray, F;Pisani, P
通讯作者：
Pisani, P
影响因子：
45.3
作者：
Breathnach, OS;Freidlin, B;Johnson, BE
通讯作者：
Johnson, BE